Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19059423 | 1.00 | KIF11 (0.60) | KIF11CA4KCNH2LTA4HCA12 | |
| SCHEMBL23795102 | 0.92 | CA1 (0.52) | KIF11CA4LTA4HCA12CA1 | |
| SCHEMBL977257 | 0.86 | KIF11 (0.62) | KIF11CA4KCNH2LTA4HCA12 | |
| SCHEMBL2879044 | 0.86 | KIF11 (0.62) | KIF11CA4KCNH2LTA4HCA12 | |
| SCHEMBL84106 | 0.82 | KIF11 (0.44) | KIF11 | |
| SCHEMBL19514691 | 0.82 | KIF11 (0.58) | KIF11CA4KCNH2LTA4HCA12 | |
| SCHEMBL977258 | 0.82 | KIF11 (0.58) | KIF11CA4KCNH2LTA4HCA12 | |
| SCHEMBL291841 | 0.82 | KIF11 (0.58) | KIF11CA4KCNH2LTA4HCA12 | |
| SCHEMBL31396388 | 0.82 | KIF11 (0.58) | KIF11CA4KCNH2LTA4HCA12 | |
| SCHEMBL2689280 | 0.81 | CA4 (0.56) | KIF11CA4KCNH2LTA4HCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032623-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032623-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | TEK, IGF2BP1, METTL16 | KIF11 101/4885CA4 4135/4885KCNH2 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.